Cited by

• Highlight on advances in nontuberculous mycobacterial disease in North America.

  Mirsaeidi M, Farshidpour M, Allen MB, Ebrahimi G, Falkinham JO. Mirsaeidi M, et al. Biomed Res Int. 2014;2014:919474. doi: 10.1155/2014/919474. Epub 2014 Sep 11. Biomed Res Int. 2014. PMID: 25574470 Free PMC article. Review.
• Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis.

  Qvist T, Pressler T, Høiby N, Katzenstein TL. Qvist T, et al. Respir Res. 2014 Apr 11;15(1):41. doi: 10.1186/1465-9921-15-41. Respir Res. 2014. PMID: 24725650 Free PMC article.
• US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

  Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. Floto RA, et al. Thorax. 2016 Jan;71 Suppl 1(Suppl 1):i1-22. doi: 10.1136/thoraxjnl-2015-207360. Thorax. 2016. PMID: 26666259 Free PMC article.
• Highlights from the 2016 North American Cystic Fibrosis Conference.

  Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T, Muhlebach MS. Zemanick ET, et al. Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. doi: 10.1002/ppul.23707. Epub 2017 Jul 11. Pediatr Pulmonol. 2017. PMID: 28696526 Free PMC article. Review.
• A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.

  Kaur P, Krishnamurthy RV, Shandil RK, Mohan R, Narayanan S. Kaur P, et al. Pathogens. 2023 Dec 31;13(1):40. doi: 10.3390/pathogens13010040. Pathogens. 2023. PMID: 38251347 Free PMC article.